Interview with Riccardo Carbucicchio, President and CEO of NTC.

Interview with Riccardo Carbucicchio, President and CEO of NTC.

  • Jan 27, 2020

Recently you announced that for NTC the trend topic of 2020 will be “Execution is the strategy”. What does this mean concretely, for you?

At NTC in the last few years we have worked hard to develop and register many new medical devices and develop full new registration dossiers for several drugs. In 2019 we accomplished to complete a couple of dozens of such developments. Therefore for NTC 2020 will be the year where our strategy will translate into execution.

“Execution is the strategy” can be declined in the following main objectives:

  • to strike new important partnering out licensing deals to unleash the potential of the NTC novelties
  • to support our partners with crisp and compelling marketing communication, rich of evidence-based data
  • to keep on carry on our key R&D projects and to execute our large clinical programs in close cooperation with the scientific community
  • to reinforce in the NTC people the pride of being part of an exciting journey, further fostering and encouraging their potential and mindset through autonomy, learning and embracing change.

What about NTC business goals?                                                   

In our B2B model, our core business, we aim to build long-term partnerships based on smart commercial solutions to respond to unmet medical needs. We aim to reinforce our business in our core areas, being ophthalmology, gynaecology, pediatrics and GI. We plan to be present at the major congresses in Europe of these therapeutic areas, and to foster the opportunity of CPhI being in Milan in 2020, where NTC is headquartered.

What makes you different from the competition?

NTC stands for Novelty, Technology to best take Care of the patients. We try to fuel all our products with our value proposition to make them stand out in the industry. We consider fundamental to be able to add more science leveraging global data, digital technologies and in general with large data analytics. I like to say that instead of products, we offer therapeutic solutions to respond to unmet medical needs.

Regarding R&D projects, could you tell us more about the core focus you have?

Antibiotic Resistance (ABR) is a major health topic. We got inspired by the programs of the World Health Organization aiming at fighting against antibiotic resistance. Many Global and EU institutions have in their core objectives programs meant to find novelties to respond to this huge emerging problem. NTC is engaged in a variety of clinical programs designed to rationalize the use of antibiotic therapy particularly in ophthalmology and in pediatrics. On top of that we have over 30 R&D projects running, and most of them are meant to address ABR.

More and more companies declare that People are a fundamental asset.

NTC is continuously working to be a great place work, where our employees and consultants can feel at ease and in a positive and health environment. We embraced ESG (Environmental, Social and Governance) to challenge ourselves to become better and better.

We try all together to keep our Values fresh and updated in everyone at NTC: Passion, Trust and Transparency, Accountability, Sense of Urgency drive daily our will to be. I personally value a lot the human touch, and I try my best to ensure that our happiness index keeps very high.

Results, goals… what about strategy?

I recently read about a global survey of 700 executives across a variety of industries which stated that only 8% of company leaders were said to excel both in strategy and in execution. It added that experience and research suggest that the days of keeping strategy and execution as separate topics are ending, we need leaders that can create big promises to customers and help their organizations deliver on those promises. I want to be there.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. READ MORE